Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weeks

Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented as part of the “Best of the Best at Maui Derm” late breakers session at Maui Derm Hawaii 2026.

Improvements in skin clearance, itch, and quality of life observed at Week 16 were sustained through Week 52. Most adolescents who experienced disease flare after treatment withdrawal regained response following retreatment.

“Risankizumab was well tolerated through 52 weeks, with a safety profile generally consistent with adult studies,” the authors reported.

Jason E. Hawkes, MD, noted that treatment options for pediatric psoriasis are still limited, but that this progress is important.

“Having an IL-23 inhibitor that shows continued improvement out to 52 weeks, with infrequent dosing, is a meaningful expansion of our therapeutic toolbox,” he said. “These patients continue to improve over time, which reinforces the durability of IL-23 blockade even in younger populations.”